Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (41-50 of 319) with videos related to

Pageof 32
Sort By:
Journal of Osteoporosis|October 21, 2011
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male OsteoporosisAlicia K Morgans, Matthew R Smith
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancerPhilip J Saylor, Matthew R Smith
Bone|October 19, 2010
Foreword: skeletal complications of cancerMatthew R Smith, T John Martin
The Journal of Urology|December 14, 2012
Metabolic complications of androgen deprivation therapy for prostate cancerPhilip J Saylor, Matthew R Smith
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2013
Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?Richard J Lee, Matthew R Smith
Journal of Crohn'S & Colitis|February 11, 2014
Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and reviewMatthew R Smith, Sheldon C Cooper
The Urologic Clinics of North America|October 23, 2012
Bone-targeted agents: preventing skeletal complications in prostate cancerAlicia K Morgans, Matthew R Smith
Urology|May 12, 2005
Future therapies in hormone-refractory prostate cancerMatthew R Smith, Joel B Nelson
Cancer Journal (Sudbury, Mass.)|January 23, 2013
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerRichard J Lee, Matthew R Smith
Current Opinion in Endocrinology, Diabetes, and Obesity|April 21, 2010
Metabolic sequelae associated with androgen deprivation therapy for prostate cancerJason E Faris, Matthew R Smith
Pageof 32

Showing results (41-50 of 319) with videos related to

Sort By:
Pageof 32
Journal of Osteoporosis|October 21, 2011
RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male OsteoporosisAlicia K Morgans, Matthew R Smith
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancerPhilip J Saylor, Matthew R Smith
Bone|October 19, 2010
Foreword: skeletal complications of cancerMatthew R Smith, T John Martin
The Journal of Urology|December 14, 2012
Metabolic complications of androgen deprivation therapy for prostate cancerPhilip J Saylor, Matthew R Smith
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2013
Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?Richard J Lee, Matthew R Smith
Journal of Crohn'S & Colitis|February 11, 2014
Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and reviewMatthew R Smith, Sheldon C Cooper
The Urologic Clinics of North America|October 23, 2012
Bone-targeted agents: preventing skeletal complications in prostate cancerAlicia K Morgans, Matthew R Smith
Urology|May 12, 2005
Future therapies in hormone-refractory prostate cancerMatthew R Smith, Joel B Nelson
Cancer Journal (Sudbury, Mass.)|January 23, 2013
Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerRichard J Lee, Matthew R Smith
Current Opinion in Endocrinology, Diabetes, and Obesity|April 21, 2010
Metabolic sequelae associated with androgen deprivation therapy for prostate cancerJason E Faris, Matthew R Smith
Pageof 32